Amgen said the US District Court in Boston has entered final judgment and a permanent injunction against Roche prohibiting it from selling its anaemia drug Mircera in the US and ending a five-year patent dispute.

During the dispute, Roche admitted that five Amgen EPO patents involved in the lawsuit were valid, and Amgen’s Aranesp anaemia drug, already selling in the US market, would be affected if Roche entered the market with Mircera.

The settlement did not conclude on financial payments but did iron out issues with the validity of patents, according to Amgen senior vice-president David Scott.

“We are very pleased with this agreement, a victory for Amgen that reaffirms the validity of our patents and brings to an end this long-standing legal dispute,” Scott said.

“The settlement provides certainty to both companies and allows Amgen to focus intently on investing in innovative research and delivering medicines that treat grievous, unmet medical needs.”